Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Stock Is Marching Higher Today

By George Budwell - Updated Feb 13, 2020 at 1:57PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Here's why it has officially doubled in value since the start of 2020.

What happened

Novavax (NVAX 8.23%), a late-stage vaccine developer, is extending its recent winning streak today. The biotech's shares were up by 10% as of 12:40 p.m. EST on Thursday. As a result, Novavax's stock has exactly doubled in value since the start of 2020. 

What's lighting a fire underneath the biotech's shares in early 2020? There are two possibilities here:

  1. The coronavirus outbreak that originated in China but has since spread to dozens of countries has been a huge catalyst for several biotechs over the past six weeks. Novavax, for its part, has been one of the big winners in the coronavirus space, thanks to the company's push to develop a vaccine in record time.
  2. The second probable catalyst is the company's forthcoming late-stage NanoFlu data slated to hit the wires before the end of March.   
The word coronavirus displayed against a blue background, with two red balls with spikes that represent the virus set nearby.

Image source: Getty Images.

So what

The coronavirus threat, while serious, is likely to turn out to be a nonevent for developmental stage biotechs like Novavax. Most experts believe the current outbreak will ultimately peter out by summer. So even though Novavax and other vaccine specialists are striving to develop a vaccine as soon as possible, there's little chance that one will be available for testing before the threat is gone. In short, there's no reason to buy Novavax's stock in response to this viral outbreak.

The NanoFlu data, on the other hand, could be a significant market-moving event for the company. There's a clear need for better flu vaccines, and NanoFlu could fill this treatment gap. That's a big deal because the global flu vaccine market is currently worth upward of $2 billion a year. 

Now what

Novavax's stock is a high-risk, high-reward play. If NanoFlu turns out to be a major improvement over the currently available cohort of flu vaccines, there's a good chance that one or more suitors will emerge from the shadows. By contrast, another late-stage failure for the company's vaccine platform will surely spell disaster for its share price. As such, this small-cap vaccine stock is arguably only suited for investors with an extremely high tolerance for risk.  

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$51.95 (8.23%) $3.95

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
338%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.